Effective antitumour immunity depends on the orchestration of potent T cell responses
against malignancies. Regression of human cancers has been induced by immune …

Tumor-cell apoptosis is the basis of many cancer therapies,,, and tumor-specific T cells are
the principal effectors of successful antitumor immunotherapies,,,. Here we show that …

Adoptively transferred T cells and agents designed to block the CD47–SIRPα axis are
promising cancer therapeutics that activate distinct arms of the immune system,. Here we …

Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to
directly recognize and kill tumour cells,–. These strategies are limited by the emergence of …

Immune checkpoint inhibitors result in impressive clinical responses,,,, but optimal results
will require combination with each other and other therapies. This raises fundamental …

Despite the significant therapeutic advances provided by immune-checkpoint blockade and
chimeric antigen receptor T cell treatments, many malignancies remain unresponsive to …

Antitumour immunity gets a boost | Nature Skip to main content Thank you for visiting nature.com.
You are using a browser version with limited support for CSS. To obtain the best experience …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

The peripheral T cell repertoire of healthy individuals contains self-reactive T cells,.
Checkpoint receptors such as PD-1 are thought to enable the induction of peripheral …